KR970706018A - 백신 조성물(vaccine compositions) - Google Patents
백신 조성물(vaccine compositions)Info
- Publication number
- KR970706018A KR970706018A KR1019970702172A KR19970702172A KR970706018A KR 970706018 A KR970706018 A KR 970706018A KR 1019970702172 A KR1019970702172 A KR 1019970702172A KR 19970702172 A KR19970702172 A KR 19970702172A KR 970706018 A KR970706018 A KR 970706018A
- Authority
- KR
- South Korea
- Prior art keywords
- vaccine composition
- chitosan
- neuraminidase
- influenza virus
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 22
- 229960005486 vaccine Drugs 0.000 title claims abstract 15
- 229920001661 Chitosan Polymers 0.000 claims abstract 12
- 239000000427 antigen Substances 0.000 claims abstract 11
- 102000036639 antigens Human genes 0.000 claims abstract 11
- 108091007433 antigens Proteins 0.000 claims abstract 11
- 102000005348 Neuraminidase Human genes 0.000 claims abstract 9
- 108010006232 Neuraminidase Proteins 0.000 claims abstract 9
- 241000712461 unidentified influenza virus Species 0.000 claims abstract 9
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract 8
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract 8
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract 8
- 101710176177 Protein A56 Proteins 0.000 claims abstract 8
- 239000000185 hemagglutinin Substances 0.000 claims abstract 8
- 230000028993 immune response Effects 0.000 claims abstract 2
- 206010022000 influenza Diseases 0.000 claims abstract 2
- 230000009885 systemic effect Effects 0.000 claims abstract 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 4
- 230000002787 reinforcement Effects 0.000 claims 2
- 229920002101 Chitin Polymers 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000016379 mucosal immune response Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 헤마글리티닌 및 뉴라미니다아제 인플루엔자 바이러스 항원과 같은 인플루엔자 바이러스 항원(들), 및 보강적으로 유효량의 키토산을 포함하는 점막 투여용, 특히 비내 투여용 백신 조성물에 관한 것이다. 본 발명의 조성물은 인플루엔자에 이한 감염에 대하여 숙주를 면역시키기 위해 사용될 수 있고, 조성물중의 키토산은 방어 IgA 점막 면역 반응 및 IgG 전신 면역 반응의 자극을 증강시키는 작용을 한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (17)
- 인플루엔자 바이러스 항원 및 보강적으로 유효량의 키토산을 포함하는 점막 투여용 백신 조성물.
- 제1항에 있어서, 비내 투여용 백신 조성물.
- 제1항 또는 제2항에 있어서, 헤마글루티닌 및 뉴라미니다아제 인플루엔자 바이러스 항원을 모두 함유하는 백신 조성물.
- 제1항에 있어서, 정제 헤마글리투닌 및 뉴라미니다아제 인플루엔자 바이러스 항원, 및 보강적으로 유효량의 키토산을 포함하는 비내 투여용 백신 조성물.
- 제3항 또는 제4항에 있어서, 헤마글루티닌 및 뉴라미니다아제 인플루엔자가 10 내지 25 나노미터의 반경을 갖는 로제트 형태로 존재함을 특징으로 하는 백신 조성물.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 키토산이 80% 이상 탈아세틸화된 탈아세틸화 키틴임을 특징으로 하는 백신 조성물.
- 제6항에 있어서, 키토산이 85%이상 탈아세틸화됨을 특징으로 하는 백신 조성물.
- 제7항에 있어서, 키토산이 88% 내지 90% 탈아세틸화됨을 특징으로 하는 백신 조성물.
- 제1항 내지 제8항 중 어느 한 항에 있어서, 키토산이 수용성임을 특징으로 하는 백신 조성물.
- 제1항 내지 제9항 중 어느 한 항에 있어서, 조성물의 pH가 5.5 내지 6.5임을 특징으로 하는 백신 조성물.
- 제10항에 있어서, pH가 약 6임을 특징으로 하는 백신 조성물.
- 제1항 내지 제11항 중 어느 한 항에 따른 백신 조성물과 함께 이 조성물을 비내적으로 전달시키시 위한 투여 장치를 포함하느 약제.
- 제12항에 있어서, 투여 장치가 에어로졸 전달 시스템임을 특징으로 하는 약제품.
- 정제 헤마글루티닌 및 뉴라미니다아제 항원의 혼합물과 같은 인플루엔자 바이러스 항원을 보강적으로 유효량의 키토산과 함께 포함하는 제1항 내지 제11항 중 어느 한 항에 따른 백신 조성물을 숙주의 점막 표면에 투여하는 것을 포함하는, 인플루엔자에 이한 감염에 대해 숙주를 면역시키는 방법.
- 정제 헤마글리투티닌 및 뉴라미니다아제 항원의 혼합물과 같은 인플루엔자 바이러스 항원을 보강적으로 유효량의 키토산과 함께 포함하는 제1항 내지 제11항 중 어느 한 항에 따른 백신 조성물을 환자의 전막 표면에 투여함으로써 방어 IgA점막 면역 반응 및 IgG 전신 면역 반응을 증강시키는 방법.
- 비내 투여시키는 경우에, 헤마글루티닌 및 뉴라미니다아제와 함께 제1항 내지 제11항 중 어느 한 항에 따른 키토산을 공동-투여시킴으로써 헤마글루티닌 및 뉴라미니다아제와 같은 인플루엔자 바이러스 항원의 면역 반응을 증강시키는 방법.
- 비내 투여시키는 경우에 정제 헤마글루티닌 및 뉴라미니다아제와 같은 인플루엔자 바이러스 항원의 면역 원성을 증강시키기 위한 비내 투여용 보강 조성물을 제조하기 위해 제1항 내지 제16항 중 어느 한 항에 따른 키토산을 사용하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9419979A GB9419979D0 (en) | 1994-10-04 | 1994-10-04 | Vaccine compositions |
| GB9419979.1 | 1994-10-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR970706018A true KR970706018A (ko) | 1997-11-03 |
| KR100373593B1 KR100373593B1 (ko) | 2003-05-09 |
Family
ID=10762310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019970702172A KR100373593B1 (ko) | 1994-10-04 | 1995-09-21 | 백신조성물 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6048536A (ko) |
| EP (1) | EP0784485B8 (ko) |
| JP (1) | JP4240237B2 (ko) |
| KR (1) | KR100373593B1 (ko) |
| CN (1) | CN1097467C (ko) |
| AT (1) | ATE229816T1 (ko) |
| AU (1) | AU710930B2 (ko) |
| BR (1) | BR9509190A (ko) |
| CA (1) | CA2201598C (ko) |
| DE (1) | DE69529224T2 (ko) |
| DK (1) | DK0784485T3 (ko) |
| ES (1) | ES2192582T3 (ko) |
| GB (1) | GB9419979D0 (ko) |
| MX (1) | MX9702336A (ko) |
| NZ (1) | NZ292953A (ko) |
| TW (1) | TW426521B (ko) |
| WO (1) | WO1996010421A1 (ko) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE212378T1 (de) | 1993-06-04 | 2002-02-15 | Whitehead Biomedical Inst | Stressproteine und ihre verwendung |
| US5912000A (en) * | 1994-09-23 | 1999-06-15 | Zonagen, Inc. | Chitosan induced immunopotentiation |
| AU754675B2 (en) * | 1995-11-01 | 2002-11-21 | Archimedes Development Limited | Influenza vaccine compositions |
| GB9522351D0 (en) * | 1995-11-01 | 1996-01-03 | Medeva Holdings Bv | Vaccine compositions |
| GB9525083D0 (en) | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| DE69735376T2 (de) * | 1996-11-26 | 2006-12-14 | Stressgen Biotechnologies Corp., Victoria | Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort |
| US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
| GB9700624D0 (en) | 1997-01-14 | 1997-03-05 | Danbiosyst Uk | Drug delivery composition |
| AU771525B2 (en) * | 1997-03-25 | 2004-03-25 | Zonagen, Inc. | Chitosan induced immunopotentiation |
| CA2255867C (en) * | 1997-03-25 | 2008-02-05 | Zonagen, Inc. | Chitosan induced immunopotentiation |
| US5980912A (en) * | 1997-03-25 | 1999-11-09 | Zonagen, Inc. | Chitosan induced immunopotentiation |
| CA2298840A1 (en) | 1997-08-05 | 1999-02-18 | Stressgen Biotechnologies Corporation | Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| CU22871A1 (es) * | 1998-12-02 | 2003-10-21 | Ct Ingenieria Genetica Biotech | Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal |
| US6497880B1 (en) | 1998-12-08 | 2002-12-24 | Stressgen Biotechnologies Corporation | Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
| ATE403436T1 (de) * | 1999-03-24 | 2008-08-15 | Secr Defence | Polykationische karbohydrate als immunostimulierende mittel in impstoffen |
| JP2003504074A (ja) | 1999-07-08 | 2003-02-04 | ストレスゲン バイオテクノロジーズ コーポレイション | インビトロでのＴｈ１様応答の誘導 |
| WO2001051081A1 (en) | 2000-01-14 | 2001-07-19 | Whitehead Institute For Biomedical Research | In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
| DK1296711T3 (da) | 2000-06-26 | 2006-08-28 | Stressgen Biotechnologies Corp | HPV-E7 til behandling af humant papillomavirus |
| ITMI20010571A1 (it) * | 2001-03-19 | 2002-09-19 | Grisotech S A | Vaccini assorbibili per via trans-mucosale |
| US20040077540A1 (en) * | 2002-06-28 | 2004-04-22 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| EP1594536B1 (en) * | 2003-01-30 | 2009-03-25 | Novartis Vaccines and Diagnostics, Inc. | Adjuvanted influenza vaccine |
| CN1301131C (zh) * | 2003-04-11 | 2007-02-21 | 上海欣安基因免疫与疫苗研究开发有限公司 | 一种病毒性心肌炎基因疫苗及其制备方法和应用 |
| CA2523870A1 (en) * | 2003-04-30 | 2004-11-18 | Nastech Pharmaceutical Company Inc. | Claudins' underexpression as markers of tumor metastasis |
| GB0315632D0 (en) | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
| US20050129679A1 (en) * | 2003-12-15 | 2005-06-16 | Nastech Pharmaceutical Company Inc. | Method for opening tight junctions |
| KR20070108371A (ko) * | 2005-01-05 | 2007-11-09 | 필라델피아 헬스 앤드 에듀케이션 코퍼레이션 | 전달 비히클, 생물활성 물질 및 바이러스 백신 |
| CN100425288C (zh) * | 2005-01-28 | 2008-10-15 | 北京金迪克生物技术研究所 | 鼻腔喷雾型流感病毒灭活疫苗及其制备方法 |
| CA2552596A1 (en) * | 2005-08-09 | 2007-02-09 | Solvay Pharmaceuticals B.V. | Methods and systems for determining mid-value titers |
| CN101450208B (zh) * | 2008-12-31 | 2011-08-31 | 中国人民解放军军事医学科学院微生物流行病研究所 | 喷鼻免疫流感多价疫苗的制备及其方法 |
| EP2308506A1 (en) * | 2009-10-02 | 2011-04-13 | Mucosis B.V. | Adjuvanted intranasal vaccine formulations |
| WO2016199904A1 (ja) * | 2015-06-10 | 2016-12-15 | 国立大学法人東京大学 | ワクチン用アジュバント、ワクチン、及び免疫誘導方法 |
| GB2596820A (en) * | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57136528A (en) * | 1981-02-09 | 1982-08-23 | Hayashibara Biochem Lab Inc | Preparation of viral vaccine |
| CA1261264A (en) * | 1984-11-29 | 1989-09-26 | Shigeo Suzuki | Immunopotentiating agents and method |
| GB8904370D0 (en) * | 1989-02-25 | 1989-04-12 | Cosmas Damian Ltd | Liquid delivery compositions |
| US5169840A (en) * | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
| JP3109886B2 (ja) * | 1991-12-13 | 2000-11-20 | デンカ生研株式会社 | 経鼻接種用ワクチン |
| GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| JPH06166635A (ja) * | 1992-06-18 | 1994-06-14 | San Five Kk | 免疫アジュバント |
| GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
-
1994
- 1994-10-04 GB GB9419979A patent/GB9419979D0/en active Pending
-
1995
- 1995-09-21 DE DE69529224T patent/DE69529224T2/de not_active Expired - Lifetime
- 1995-09-21 JP JP51148896A patent/JP4240237B2/ja not_active Expired - Lifetime
- 1995-09-21 NZ NZ292953A patent/NZ292953A/en not_active IP Right Cessation
- 1995-09-21 CN CN95195504A patent/CN1097467C/zh not_active Expired - Lifetime
- 1995-09-21 BR BR9509190A patent/BR9509190A/pt not_active IP Right Cessation
- 1995-09-21 EP EP95932078A patent/EP0784485B8/en not_active Expired - Lifetime
- 1995-09-21 DK DK95932078T patent/DK0784485T3/da active
- 1995-09-21 ES ES95932078T patent/ES2192582T3/es not_active Expired - Lifetime
- 1995-09-21 KR KR1019970702172A patent/KR100373593B1/ko not_active IP Right Cessation
- 1995-09-21 WO PCT/GB1995/002231 patent/WO1996010421A1/en active IP Right Grant
- 1995-09-21 US US08/817,417 patent/US6048536A/en not_active Expired - Lifetime
- 1995-09-21 AT AT95932078T patent/ATE229816T1/de active
- 1995-09-21 CA CA002201598A patent/CA2201598C/en not_active Expired - Lifetime
- 1995-09-21 AU AU35269/95A patent/AU710930B2/en not_active Expired
- 1995-09-21 MX MX9702336A patent/MX9702336A/es unknown
- 1995-10-17 TW TW084110887A patent/TW426521B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0784485B8 (en) | 2003-05-02 |
| EP0784485A1 (en) | 1997-07-23 |
| JP4240237B2 (ja) | 2009-03-18 |
| MX9702336A (es) | 1997-06-28 |
| BR9509190A (pt) | 1997-10-21 |
| AU710930B2 (en) | 1999-09-30 |
| NZ292953A (en) | 2001-03-30 |
| GB9419979D0 (en) | 1994-11-16 |
| TW426521B (en) | 2001-03-21 |
| KR100373593B1 (ko) | 2003-05-09 |
| DE69529224T2 (de) | 2003-07-24 |
| US6048536A (en) | 2000-04-11 |
| AU3526995A (en) | 1996-04-26 |
| DE69529224D1 (de) | 2003-01-30 |
| EP0784485B1 (en) | 2002-12-18 |
| CN1159761A (zh) | 1997-09-17 |
| CA2201598A1 (en) | 1996-04-11 |
| JPH10506405A (ja) | 1998-06-23 |
| CN1097467C (zh) | 2003-01-01 |
| WO1996010421A1 (en) | 1996-04-11 |
| CA2201598C (en) | 2006-12-12 |
| ES2192582T3 (es) | 2003-10-16 |
| DK0784485T3 (da) | 2003-04-07 |
| ATE229816T1 (de) | 2003-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970706018A (ko) | 백신 조성물(vaccine compositions) | |
| CA2236538A1 (en) | Influenza vaccine compositions | |
| DE69818707D1 (de) | Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa | |
| NZ323973A (en) | Vaccine compositions for intranasal administration comprising chitosan and use thereof | |
| ATE350057T1 (de) | Impfstoffzusammesetzung | |
| TR200100628T2 (tr) | Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler. | |
| WO2000047222A3 (de) | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation | |
| TR200100569T2 (tr) | Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler | |
| WO2002028422A3 (en) | Split enveloped virus preparation for intranasal delivery | |
| BR0014281A (pt) | Vacina contra vìrus de gripe intranasal | |
| CA2402935A1 (en) | Adjuvant for vaccines | |
| WO2003051394A3 (en) | Calcium phosphate particles as mucosal adjuvants | |
| Cheong et al. | Epigallocatechin-3-gallate as a novel vaccine adjuvant | |
| WO2000027430A3 (de) | Zusammensetzung bestehend aus influenzavirusoberflächenprotein, und abgabeeinrichtung | |
| KR960703619A (ko) | 백신 조성물(vaccine compositions) | |
| TR200100566T2 (tr) | Mukozaya yapışan(muko-adhesif)oral sıvı bileşimler | |
| WO2002036160A3 (es) | Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica | |
| AU2229997A (en) | Pharmaceutical compositions comprising natural human alpha-interferon | |
| RU94020944A (ru) | Средство для интраназальной профилактики гриппа | |
| AU754675B2 (en) | Influenza vaccine compositions | |
| BR0105968A (pt) | Medicamento natural para tratamento alternativo anti-hiv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20060210 Year of fee payment: 4 |
|
| LAPS | Lapse due to unpaid annual fee |